Kiniksa Pharmaceuticals Shares Surge Following Strong Q3 Results and Raised Full-Year Guidance
Kiniksa Pharmaceuticals (KNSA) saw its stock price rise nearly 20% to a new 52-week high following the release of its third-quarter results. The biotech company exceeded market expectations, driven primarily by the strong performance of its lead product, Arcalyst. In response to the robust quarterly growth, Kiniksa has raised its full-year financial outlook. Management anticipates that Arcalyst will achieve blockbuster status, bolstered by its strategic marketing partnership with Regeneron Pharmaceuticals.
Topics: biotechnology earnings report revenue growth stock price increase
Read the full article at Seeking Alpha
Part of the story Reddit Shares Plunge 29% Following Weak Earnings and Declining Search Traffic (31 articles)